{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-002480","form_type":"8-K","ticker":"CYTK","cik":"0001061983","company_name":"CYTOKINETICS INC","filed_at":"2022-04-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.570103+00:00","generated_at":"2026-06-26T08:24:39.973587+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Cytokinetics appoints Robert Harrington as director; Dr. Gage resigns, Henderson becomes Chairman","bullets":["Robert A. Harrington, M.D. appointed to Board, term through 2024 annual meeting; also joins Science and Technology Committee.","Dr. Harrington receives $45,000 annual retainer (pro-rated) and option for 35,000 shares vesting over 3 years.","L. Patrick Gage, Ph.D. resigns as director; not due to any disagreement with the company.","John T. Henderson, M.D. appointed as Chairman of the Board following Dr. Gage's resignation."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-002480","json":"https://secwatch.observer/filing/0001171843-22-002480.json","markdown":"https://secwatch.observer/filing/0001171843-22-002480.md","text":"https://secwatch.observer/filing/0001171843-22-002480.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1061983/000117184322002480/0001171843-22-002480-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1061983/000117184322002480/f8k_040822.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T08:24:39.973587+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2832bdccc7","claim":"L. Patrick Gage resigned as Director at CYTOKINETICS INC.","evidence_excerpt":"Also on the Effective Date, L. Patrick Gage, Ph.D. resigned as a director of Cytokinetics.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000117184322002480/0001171843-22-002480-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"3a20ba9e6c","claim":"Robert A. Harrington was appointed as Director at CYTOKINETICS INC.","evidence_excerpt":"On April 8, 2022, (the “Effective Date”), the Board of Directors (the “Board”) of Cytokinetics, Incorporated (the “Company”) appointed, upon the recommendation of the Nominating and Governance Committee of the Board, Robert A. Harrington, M.D. to fill a vacant Board seat and to serve as a member of the Board with an initial term expiring at the Company’s 2024 annual meeting of stockholders.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000117184322002480/0001171843-22-002480-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"5a44845077","claim":"John T. Henderson was appointed as Chairman of the Board at CYTOKINETICS INC.","evidence_excerpt":"As a result of Dr. Gage’s resignation, John T. Henderson, M.D. was appointed as Chairman of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000117184322002480/0001171843-22-002480-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chairman of the Board"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}